O	0	7	Effects
O	8	10	on
O	11	18	quality
O	19	21	of
O	22	26	life
O	27	29	of
O	30	36	weekly
B-intervention	37	46	docetaxel
I-intervention	46	47	-
I-intervention	47	52	based
I-intervention	53	65	chemotherapy
O	66	68	in
B-eligibility	69	77	patients
I-eligibility	78	82	with
I-eligibility	83	90	locally
I-eligibility	91	99	advanced
I-eligibility	100	102	or
I-eligibility	103	113	metastatic
I-eligibility	114	120	breast
I-eligibility	121	127	cancer
O	127	128	:
O	129	136	results
O	137	139	of
O	140	141	a
O	142	148	single
O	148	149	-
O	149	155	centre
O	156	166	randomized
O	167	172	phase
O	173	174	3
O	175	180	trial
O	180	181	.

O	182	184	To
O	185	193	evaluate
O	194	201	whether
O	202	208	weekly
O	209	218	schedules
O	219	221	of
O	222	231	docetaxel
O	231	232	-
O	232	237	based
O	238	250	chemotherapy
O	251	255	were
O	256	264	superior
O	265	267	to
O	268	269	3
O	269	270	-
O	270	276	weekly
O	277	281	ones
O	282	284	in
O	285	290	terms
O	291	293	of
O	294	301	quality
O	302	304	of
O	305	309	life
O	310	312	in
O	313	320	locally
O	321	329	advanced
O	330	332	or
O	333	343	metastatic
O	344	350	breast
O	351	357	cancer
O	357	358	.

O	359	367	Patients
O	368	372	with
O	373	380	locally
O	381	389	advanced
O	390	392	or
O	393	403	metastatic
O	404	410	breast
O	411	417	cancer
O	417	418	,
O	419	423	aged
B-age	424	425	â‰¤
I-age	426	428	70
I-age	429	434	years
O	434	435	,
O	436	447	performance
O	448	454	status
O	455	456	0
O	456	457	-
O	457	458	2
O	458	459	,
O	460	472	chemotherapy
O	472	473	-
O	473	478	naive
O	479	482	for
O	483	493	metastatic
O	494	501	disease
O	501	502	,
O	503	507	were
O	508	516	eligible
O	516	517	.

O	518	522	They
O	523	527	were
O	528	538	randomized
O	539	541	to
O	542	548	weekly
O	549	551	or
O	552	553	3
O	553	554	-
O	554	560	weekly
O	561	572	combination
O	573	575	of
O	576	585	docetaxel
O	586	589	and
O	590	600	epirubicin
O	600	601	,
O	602	604	if
O	605	609	they
O	610	614	were
O	615	618	not
O	619	626	treated
O	627	631	with
O	632	640	adjuvant
O	641	655	anthracyclines
O	655	656	,
O	657	659	or
O	660	669	docetaxel
O	670	673	and
O	674	686	capecitabine
O	686	687	,
O	688	690	if
O	691	698	treated
O	699	703	with
O	704	712	adjuvant
O	713	727	anthracyclines
O	727	728	.

O	729	736	Primary
O	737	740	end
O	740	741	-
O	741	746	point
O	747	750	was
B-outcome-Measure	751	757	global
I-outcome-Measure	758	765	quality
I-outcome-Measure	766	768	of
I-outcome-Measure	769	773	life
I-outcome-Measure	774	780	change
I-outcome-Measure	781	783	at
I-outcome-Measure	784	785	6
I-outcome-Measure	785	786	-
I-outcome-Measure	786	791	weeks
O	791	792	,
O	793	801	measured
O	802	804	by
O	805	810	EORTC
O	811	814	QLQ
O	814	815	-
O	815	818	C30
O	818	819	.

O	820	824	With
O	825	828	two
O	828	829	-
O	829	834	sided
O	835	840	alpha
O	841	842	0
O	842	843	.
O	843	845	05
O	846	849	and
O	850	852	80
O	852	853	%
O	854	859	power
O	860	863	for
O	864	866	35
O	866	867	%
O	868	874	effect
O	875	879	size
O	879	880	,
O	881	884	130
O	885	893	patients
O	894	897	per
O	898	901	arm
O	902	906	were
O	907	913	needed
O	913	914	.

O	915	919	From
O	920	928	February
O	929	933	2004
O	934	936	to
O	937	942	March
O	943	947	2008
O	947	948	,
B-total-participants	949	952	139
O	953	961	patients
O	962	966	were
O	967	977	randomized
O	977	978	,
B-intervention-participants	979	981	70
O	982	984	to
O	985	991	weekly
O	992	995	and
B-control-participants	996	998	69
O	999	1001	to
B-control	1002	1003	3
I-control	1003	1004	-
I-control	1004	1010	weekly
I-control	1011	1014	arm
O	1014	1015	;
O	1016	1019	129
O	1020	1023	and
O	1024	1026	89
O	1027	1035	patients
O	1036	1042	filled
O	1043	1051	baseline
O	1052	1055	and
O	1056	1057	6
O	1057	1058	-
O	1058	1062	week
O	1063	1077	questionnaires
O	1077	1078	,
O	1079	1091	respectively
O	1091	1092	.

O	1093	1099	Global
B-outcome	1100	1107	quality
I-outcome	1108	1110	of
I-outcome	1111	1115	life
O	1116	1119	was
O	1120	1126	better
O	1127	1129	in
O	1130	1133	the
O	1134	1135	3
O	1135	1136	-
O	1136	1142	weekly
O	1143	1146	arm
O	1147	1148	(
O	1148	1149	p
O	1150	1151	=
O	1152	1153	0
O	1153	1154	.
O	1154	1156	03
O	1156	1157	)
O	1157	1158	;
O	1159	1167	patients
O	1168	1175	treated
O	1176	1180	with
O	1181	1187	weekly
O	1188	1197	schedules
O	1198	1207	presented
O	1208	1209	a
O	1210	1223	significantly
O	1224	1233	worsening
O	1234	1236	in
O	1237	1241	role
O	1242	1253	functioning
O	1254	1257	and
O	1258	1267	financial
O	1268	1274	scores
O	1275	1276	(
O	1276	1277	p
O	1278	1279	=
O	1280	1281	0
O	1281	1282	.
O	1282	1284	02
O	1285	1288	and
O	1289	1290	p
O	1291	1292	<
O	1293	1294	0
O	1294	1295	.
O	1295	1298	001
O	1298	1299	)
O	1299	1300	.

B-outcome	1301	1312	Neutropenia
I-outcome	1313	1316	and
I-outcome	1317	1327	stomatitis
O	1328	1332	were
O	1333	1338	worse
O	1339	1341	in
O	1342	1345	the
O	1346	1347	3
O	1347	1348	-
O	1348	1354	weekly
O	1355	1358	arm
O	1358	1359	,
O	1360	1365	where
B-cv-bin-abs	1366	1369	two
O	1370	1375	toxic
B-outcome	1376	1382	deaths
O	1383	1387	were
O	1388	1396	observed
O	1396	1397	.

B-outcome	1398	1405	Overall
I-outcome	1406	1414	response
I-outcome	1415	1419	rate
O	1420	1423	was
B-cv-bin-percent	1424	1426	39
I-cv-bin-percent	1426	1427	.
I-cv-bin-percent	1427	1428	1
I-cv-bin-percent	1428	1429	%
O	1430	1433	and
B-iv-bin-percent	1434	1436	33
I-iv-bin-percent	1436	1437	.
I-iv-bin-percent	1437	1438	3
I-iv-bin-percent	1438	1439	%
O	1440	1442	in
O	1443	1444	3
O	1444	1445	-
O	1445	1451	weekly
O	1452	1455	and
O	1456	1462	weekly
O	1463	1467	arms
O	1467	1468	;
O	1469	1475	hazard
O	1476	1481	ratio
O	1482	1484	of
B-outcome	1485	1496	progression
O	1497	1500	was
O	1501	1502	1
O	1502	1503	.
O	1503	1505	29
O	1506	1507	(
O	1507	1509	95
O	1509	1510	%
O	1511	1513	CI
O	1513	1514	:
O	1515	1516	0
O	1516	1517	.
O	1517	1519	84
O	1519	1520	-
O	1520	1521	1
O	1521	1522	.
O	1522	1524	97
O	1524	1525	)
O	1526	1529	and
O	1530	1536	hazard
O	1537	1542	ratio
O	1543	1545	of
B-outcome	1546	1551	death
O	1552	1555	was
O	1556	1557	1
O	1557	1558	.
O	1558	1560	38
O	1561	1562	(
O	1562	1564	95
O	1564	1565	%
O	1566	1568	CI
O	1568	1569	:
O	1570	1571	0
O	1571	1572	.
O	1572	1574	82
O	1574	1575	-
O	1575	1576	2
O	1576	1577	.
O	1577	1579	30
O	1579	1580	)
O	1581	1583	in
O	1584	1587	the
O	1588	1594	weekly
O	1595	1598	arm
O	1598	1599	.

O	1600	1602	In
O	1603	1607	this
O	1608	1613	trial
O	1613	1614	,
O	1615	1618	the
O	1619	1625	weekly
O	1626	1635	schedules
O	1636	1638	of
O	1639	1648	docetaxel
O	1648	1649	-
O	1649	1654	based
O	1655	1667	chemotherapy
O	1668	1674	appear
O	1675	1677	to
O	1678	1680	be
O	1681	1689	inferior
O	1690	1692	to
O	1693	1696	the
O	1697	1698	3
O	1698	1699	-
O	1699	1705	weekly
O	1706	1709	one
O	1710	1712	in
O	1713	1718	terms
O	1719	1721	of
O	1722	1729	quality
O	1730	1732	of
O	1733	1737	life
O	1738	1740	in
O	1741	1749	patients
O	1750	1754	with
O	1755	1762	locally
O	1763	1771	advanced
O	1772	1774	or
O	1775	1785	metastatic
O	1786	1792	breast
O	1793	1799	cancer
O	1799	1800	.

O	1801	1815	ClinicalTrials
O	1815	1816	.
O	1817	1820	gov
O	1821	1832	NCT00540800
O	1832	1833	.
